Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265928 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00265928 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 46 participants.
The verdict
NCT00265928, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab works in treating patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, including Waldenstrom's macroglobulinemia.
Interventions
- DRUG rituximab
- DRUG bortezomib
- PROCEDURE biological therapy
- PROCEDURE antibody therapy
- PROCEDURE enzyme inhibitor therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265928
The ClinicalTrials.gov registry entry for NCT00265928 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00265928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265928 about?
NCT00265928 is a clinical study titled "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma". RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill the...
What is the current status of trial NCT00265928?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants.
What interventions are being tested in trial NCT00265928?
The interventions under investigation include: rituximab (DRUG), bortezomib (DRUG), biological therapy (PROCEDURE), antibody therapy (PROCEDURE), enzyme inhibitor therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00265928?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.